Skip to main content

Peer Review reports

From: Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040)

Original Submission
28 Dec 2021 Submitted Original manuscript
19 May 2022 Reviewed Reviewer Report
15 Aug 2022 Reviewed Reviewer Report
2 Sep 2022 Author responded Author comments - Tomoya Fukui
Resubmission - Version 2
2 Sep 2022 Submitted Manuscript version 2
8 Oct 2022 Reviewed Reviewer Report
12 Oct 2022 Reviewed Reviewer Report
20 Oct 2022 Author responded Author comments - Tomoya Fukui
Resubmission - Version 3
20 Oct 2022 Submitted Manuscript version 3
25 Nov 2022 Reviewed Reviewer Report
4 Dec 2022 Author responded Author comments - Tomoya Fukui
Resubmission - Version 4
4 Dec 2022 Submitted Manuscript version 4
Publishing
5 Dec 2022 Editorially accepted
15 Dec 2022 Article published 10.1186/s12885-022-10409-6

You can find further information about peer review here.

Back to article page